26 April 2021
SpeeDx Receives CE-IVD Mark for PlexPCR® SARS-CoV-2
SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its PlexPCR® SARS-CoV-2* assay – a two gene test for the...
18 March 2021
SpeeDx partner with Neogen Diagnostik for distribution in Turkey
SpeeDx have announced signing a new distribution partner, further extending customer access to market-leading SpeeDx ResistancePlus® and PlexPCR® tests. Neogen Diagnostik...
18 March 2021
ResistancePlus® tests validated for cobas z 480 Analyzer
Roche customers will now have even more opportunities to utilise ResistancePlus® tests to support clinically important treatment decisions. SpeeDx ResistancePlus®...
3 February 2021
Continued Syphilis Outbreak Warrants National Attention
Syphilis remains an important public health concern due to global case increases. In Australia, the largest syphilis outbreak ever recorded...
10 November 2020
SpeeDx Partners with Nepean Hospital to Develop Risk-Based COVID-19 Management Test
SpeeDx have partnered with researchers from Nepean Hospital in an exclusive agreement to commercialise a molecular test for IFI27 -...
27 October 2020
SpeeDx opens PC2 laboratory facility
The opening of a PC2 laboratory facility at SpeeDx Sydney headquarters is an exciting milestone to celebrate. SpeeDx performs all...
